Ralf Trappe

Ralf Trappe

Auto-generated profile, based on publicly available information

Ralf Trappe

Department of Hematology and Oncology, DIAKO Ev. Diakonie-Krankenhaus Bremen, Bremen, Germany

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2012 in The Lancet Oncology
Verified
Journal Article
Closed access
RTRalf Trappe
Ralf Trappe
SOStephan Oertel
Stephan Oertel
VLVeronique Leblond
Veronique Leblond
PMPeter Mollee
Peter Mollee
MSMonica Sender
Monica Sender
SCSylvain Choquet
Sylvain Choquet

12 February 2015 in Blood
Verified
Journal Article
Open access
PDF file
ATAndreas Tiede
Andreas Tiede
RKRobert Klamroth
Robert Klamroth
RSRüdiger E. Scharf
Rüdiger E. Scharf
RTRalf U. Trappe
Ralf U. Trappe
KHKatharina Holstein
Katharina Holstein
PKPaul N. Knoebl
Paul N. Knoebl
Key Points: This study is the first to assess prognostic factors in patients with AHA treated according to a uniform immunosuppressive regimen. Residual factor VIII activity and inhibitor concentration at baseline are potentially useful predictors of remission.

1 December 2019 in The Lancet
Verified
Journal Article
Closed access
VPViola Poeschel
Viola Poeschel
GHGerhard Held
Gerhard Held
MZMarita Ziepert
Marita Ziepert
MWMathias Witzens-Harig
Mathias Witzens-Harig
HHHarald Holte
Harald Holte
MPMichael Pfreundschuh
Michael Pfreundschuh

1 May 2001 in The American Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
RTR. Trappe
R. Trappe
FLF. Laccone
F. Laccone
JCJ. Cobilanschi
J. Cobilanschi
MMM. Meins
M. Meins
PHP. Huppke
P. Huppke
WEW. Engel
W. Engel
Rett syndrome (RTT) is an X-linked neurodevelopmental disorder that apparently is lethal in male embryos. RTT almost exclusively affects female offspring and, in 99.5% of all cases, is sporadic and due to de novo mutations in the MECP2 gene. Familial cases of RTT are rare and are due to X-chromosomal inheritance from a carrier mother. We analyzed the parental origin of MECP2 mutations in sporadic cases of RTT, by analysis of linkage between the mutation in the MECP2 gene and intronic polymorphisms in 27 families with 15 different mutations, and we found a high predominance of mutations of paternal origin in 26 of 27 cases (P<.001). The paternal origin was independent of type of mutation and was found for single-base exchanges as well as for deletions. Parents were not of especially advanced age. We conclude that de novo mutations in RTT occur almost exclusively on the paternally derived X chromosome and that this is most probably the cause for the high female:male ratio observed in patients with RTT. Affected males recently have been described in a few cases of familial inheritance. Identification of the parental origin may be useful to distinguish between the sporadic form of RTT and a potentially familial form. This distinction will allow geneticists to offer more-specific counseling and discriminate between higher (maternal origin) and lower (paternal origin) recurrence risk.

28 September 2005 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
SOStephan H.K. Oertel
Stephan H.K. Oertel
EVErik Verschuuren
Erik Verschuuren
PRPetra Reinke
Petra Reinke
KZKristin Zeidler
Kristin Zeidler
MPMatthias Papp‐Váry
Matthias Papp‐Váry
HRHanno B. Riess
Hanno B. Riess
Post‐transplant lymphoproliferative disorders (PTLD) are a life‐threatening complication following solid organ transplantation. Treatment with rituximab, a humanized anti‐CD20 monoclonal antibody, has proved to be a promising approach and shown a low toxicity profile. Between February 1999 and April 2002, we conducted a multicentre phase II trial investigating rituximab as single agent in 17 patients with PTLD. Transplanted organs were heart (n = 5), kidney (n = 4), lung (n = 4) and liver (n = 4). Patients were treated with four weekly doses of 375 mg/m2 of rituximab. The mean follow‐up time is 24.2 months. Histology was distributed in 10 diffuse large cell‐, 2 marginal zone‐, 1 Burkitt‐like lymphoma, 1 Hodgkin‐like PTLD and 3 polymorphic lymphoproliferations. Therapy was well tolerated and no severe adverse events were observed. The mean overall survival period is 37.0 months with 11 patients still living. In total, 9 patients (52.9%) achieved a complete remission, with a mean duration of 17.8 months. Partial remission was observed in 1 patient, minor remission in 2 patients, no change in 3 patients and 1 patient experienced progressive disease. Two patients relapsed, at intervals 3 and 5 months after obtaining complete remission. Rituximab proved to be well tolerated and effective in the treatment of PTLD.

10 February 2017 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
RTRalf U. Trappe
Ralf U. Trappe
DDDaan Dierickx
Daan Dierickx
HZHeiner Zimmermann
Heiner Zimmermann
FMFranck Morschhauser
Franck Morschhauser
PMPeter Mollee
Peter Mollee
SCSylvain Choquet
Sylvain Choquet
Purpose: The Sequential Treatment of CD20-Positive Posttransplant Lymphoproliferative Disorder (PTLD-1) trial ( ClinicalTrials.gov identifier, NCT01458548) established sequential treatment with four cycles of rituximab followed by four cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy as a standard in the management of post-transplant lymphoproliferative disorder (PTLD) and identified response to rituximab induction as a prognostic factor for overall survival. We hypothesized that rituximab consolidation might be sufficient treatment for patients with a complete response after rituximab induction. Patients and Methods: In this prospective, international, multicenter phase II trial, 152 treatment-naive adult solid organ transplant recipients, with CD20+ PTLD unresponsive to immunosuppression reduction, were treated with four weekly doses of rituximab induction. After restaging, complete responders continued with four courses of rituximab consolidation every 21 days; all others received four courses of rituximab plus CHOP chemotherapy every 21 days. The primary end point was treatment efficacy measured as the response rate in patients who completed therapy and the response duration in those who completed therapy and responded. Secondary end points were frequency of infections, treatment-related mortality, and overall survival in the intention-to-treat population. Results: One hundred eleven of 126 patients had a complete or partial response (88%; 95% CI, 81% to 93%), of whom 88 had a complete response (70%; 95% CI, 61% to 77%). Median response duration was not reached. The 3-year estimate was 82% (95% CI, 74% to 90%). Median overall survival was 6.6 years (95% CI, 5.5 to 7.6 years). The frequency of grade 3 or 4 infections and of treatment-related mortality was 34% (95% CI, 27% to 42%) and 8% (95% CI, 5% to 14%), respectively. Response to rituximab induction remained a prognostic factor for overall survival despite treatment stratification. Conclusion: In B-cell PTLD, treatment stratification into rituximab or rituximab plus CHOP consolidation on the basis of response to rituximab induction is feasible, safe, and effective.